Pay in 4 interest-free payments of $6.48 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
Is DSIP FDA-approved
Our team will work with you to determine the most appropriate dosing schedule and discuss any available discounts or package deals to best meet your health and financial needs
BPC-157 may not be appropriate when: Imaging or specialist review has not yet been completed for a suspected structural injury There are acute red flag features (severe weakness, fever, rapid unexplained swelling, neurological changes, unexplained weight loss) The patient has active cancer or a history of certain cancers where angiogenic peptides require careful risk assessment The goal is rapid results without addressing underlying load, rehabilitation, or lifestyle drivers A peptide should not be used to delay evaluation that is clearly warranted
The reconstitution volume depends on how quickly you plan to use it
US$ 29.52
US$ 27.56
US$ 29.20
US$ 25.05
US$ 27.31
US$ 24.80
